JPH0569811B2 - - Google Patents
Info
- Publication number
- JPH0569811B2 JPH0569811B2 JP58064396A JP6439683A JPH0569811B2 JP H0569811 B2 JPH0569811 B2 JP H0569811B2 JP 58064396 A JP58064396 A JP 58064396A JP 6439683 A JP6439683 A JP 6439683A JP H0569811 B2 JPH0569811 B2 JP H0569811B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- phospholipid
- surfactant
- ulcer
- gastrointestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000003904 phospholipids Chemical class 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 30
- 239000004094 surface-active agent Substances 0.000 claims description 30
- -1 anionic phospholipid Chemical class 0.000 claims description 15
- 206010061459 Gastrointestinal ulcer Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 4
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 4
- 150000008104 phosphatidylethanolamines Chemical group 0.000 claims description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 150000008106 phosphatidylserines Chemical class 0.000 claims 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 description 16
- 208000025865 Ulcer Diseases 0.000 description 15
- KILNVBDSWZSGLL-UHFFFAOYSA-O 2-[2,3-di(hexadecanoyloxy)propoxy-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-UHFFFAOYSA-O 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 230000000767 anti-ulcer Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 8
- IBUKXRINTKQBRQ-KCKFLZCVSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-D-myo-inositol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O IBUKXRINTKQBRQ-KCKFLZCVSA-N 0.000 description 7
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 210000001156 gastric mucosa Anatomy 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000036269 ulceration Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 206010051606 Necrotising colitis Diseases 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000027119 gastric acid secretion Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000004682 mucosal barrier function Effects 0.000 description 3
- 208000011906 peptic ulcer disease Diseases 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- KLFKZIQAIPDJCW-HTIIIDOHSA-N Dipalmitoylphosphatidylserine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-HTIIIDOHSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000000266 injurious effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010023177 Jejunal ulcer Diseases 0.000 description 1
- 231100000757 Microbial toxin Toxicity 0.000 description 1
- 206010030201 Oesophageal ulcer Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010038080 Rectal ulcer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 208000028299 esophageal disease Diseases 0.000 description 1
- 208000019064 esophageal ulcer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008881 mucosal defense Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 208000037931 necrotizing enteritis Diseases 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000004347 surface barrier Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
çºæã®èæ¯
æ¬çºæã¯å»è¬çµæç©ããã³ç
æ°ã®æ²»çæ¹æ³ã«é¢
ããç¹ã«æ¬çºæã¯èè žæœ°çç ã®æ²»çããã³äºé²ã«
æçšãªãªã³è質衚é¢æŽ»æ§å€çµæç©ã«é¢ããã èè žæœ°çç ãç¹ã«æ¶åæ§æœ°çã¯ç±³åœäººå£ã®ïŒã
15ïŒ ãåããŠããã®ã§ãããæŽã«ããã®ç æ°ã¯ã
ãå·¥æ¥åããã西æŽæåã«éããããã®ã§ã¯ãª
ããäºå®ãè朰çã¯ãããæ±æŽã«ãããŠæŽã«æ·±å»
ãªåé¡ã§ãããäžã€ã®ç¹ã«å°å ç§å»ã«ããã©ããª
朰çç ã¯ãæªçãªå¹Œå ã«çºçããŠããããã®å£æ»
æ§å šè žçãšããŠç¥ãããŠããç æ ã¯1.5Kgæªæºã®
åºç£äœéãæããæ°çå ã®10ã15ïŒ ãåããã®ã§
ããããã°ãã°å€ç§æè¡ãå¿ èŠãšãããããªéã
çŽè žæœ°çãããããã®ã§ããããã®ç æ ã®åå ã¯
æ¶åæ§æœ°çãšåæ§ã«ããã€ãŠããªããããããã
äž»ããæ¬ é¥ã¯ç®¡è å·å®³å€ã«å¯Ÿããç°åžžãªç²èé²åŸ¡
æ©æ§ã«ååšãããã®ãšèããããŠããã çŸåšãåžå Žã«ã¯å€ãã®æ朰çå±åãããããã
ãã®è¬åã®æ®ãã©ã¯ãèé žåæ³ã®äžåæãã¯æå¶
ã«åãããããã®ã§ãããæ朰ççµæç©ã®èåãª
ãã®ãšããŠã¯ãæã³ãªã³äœçšå€ããã³æãã¹ã¿ã
ã³å€ããããããããã®äž¡è ã¯éæ¥çæ²»çæ段ã§
ãããèé žåæ³ã®åŠšå®³ã«å ããŠãå€ãã®æãŸãã
ãªãå¯äœçšãçããããã®æ²»ç圢æ ã¯ãé žãªãã
ã°æœ°çãªãããšãã䞻矩ã«åºã¥ããŠããã朰çã¯
èé žã®å®å šãªäžååšäžã«ãããŠã¯åœ¢æããªããã
ã«æãããããå¿ ãããå šãŠã®æœ°çæ£è ãé«ãã
ããèé žåæ³ã瀺ããšã¯éããªãããšãäžè¬çã«
èªèãããŠãããäºå®ããã矀ã®è朰çæ£è ã¯ç°
åžžã«äœãèé žæ§ãæããããã®æ§ã«ãèé žæ§ã¯å
ãªãæªåèŠå ã«ããããèè žæœ°ççºçã®äž»ããå
å ã§ã¯ãªãããšã瀺åãããŠããã 朰ççºçã®å¥ã®èª¬æãšããŠã¯ãèè žæœ°çã¯æ³å
äžã®ãèç²èéå£ãã«æ¬ é¥ãæããå人ã«çºå±ã
ããšä¿¡å¿µãå«ããã®ã§ããããã®æ¬ é¥ãšããŠã¯ã
管è å·å®³å€ïŒé žãé µçŽ ãèæ±å¡©ããã¯ããªã¢ïŒã
è¡šé¢èã«æµžéããããã®åŸæœ°çãä¿é²ãããããš
ã§ããã çŸåšã®ãšãããæ£åžžã®èè žïŒGIïŒè¡šç®ããã
èªäœåŠäœã«ããŠãããã®æ»æããå®ããã«ã€ããŠ
ã¯äžæã§ããã確ãã«ããã®åºæ¬ççåã«å¯Ÿãã
解çãé·ãæ¢çŽ¢ãããŠããŠããããšããã®ã¯ãè
ãåžžã«æ¥µç«¯ã«é žæ§ã®èçœè³ªå解æ§ç°å¢ã«æµŽããªã
ããäœæ èãããèªèº«ãæ¶åããªãã®ããšããé
説ãäŸç¶ç¢ºãã«æ®ããã®ã§ããããã§ãããå察
ã«ã朰çç ããã³å£æ»æ§å šè žçã«ãããŠåŠäœã«ã
ãŠåäœæ ã«ãã®ä¿è·èŠçŽ ãé€å»ããåã¯éããã
ãããŠããŸãã®ããšããããšã«ã€ããŠã®èšåºçã«
éèŠãªåé¡ãæ®ã€ãŠããããããã®éèŠãªåé¡ã«
察ããŠè§£çãäžããããã«ã極ããŠå€ãã®ç 究ã
è¡ãããŠãããç 究è éã¯ç²èããå¡©é žãã®ä»ã®
æœåšçã«æ¯æ§ç©è³ªã®ç®¡è ããè¡šç®ãžã®éæ¡æ£ãé²
æ¢ããæ³åäžã®ãèè žç²èéå£ãã«ããä¿è·ãã
ãŠãããšä»®å®ããŠããããã®ç²èéå£ã®ç Žå£ã®çµ
æãèè žè é£ãé²å±ãããäŸãã°ãã¢ã¹ããªã³ã
èæ±å¡©ãå¡©é žããã³ã¢ã«ã³ãŒã«ãªã©ã®åºç¯å²ã®å·
害ç©è³ªãååãªé«æ¿åºŠã§ååšããã°èè žæœ°çåã
確ãã«çãããããã®ã§ããããããã倧å€æ°ã®
æ£è ã«ããã朰çç ã®äž»ããåå ã¯ããèè žç²è
éå£ãã®çæ¥ã®æ¬ é¥ã«åž°ãããããã®ãšäžè¬çã«
æãããŠããã æ¬çºæè çã«ããæè¿ã®ç 究ã®ç€ºããšããã«ã
ãã°ãèºæ¶²ã«ååšããå€ãã®ãªã³è質ãé£éãã
çµè žã«è³ãèè žç®¡ã®é·ãã«æ²¿ã€ãŠãååšããããš
ãå€æããããããã®ãªã³è質ã¯ãæ¶åæ§ããã³
åžåæ§è¡šç®ã管è å 容ç©ããåé¢ããçµç¹ã®ç²è
è¡šé¢äžã«éäžããŠããããã§ããããããã®åå
ç©ã®æ©èœçéèŠæ§ã¯èºã«ãããŠæã詳现ã«ç 究ã
ããŠæ¥ãŠãããã®ã§ãããçŸåšã§ã¯ãèºã®è¡šé¢æŽ»
æ§å€ã¯èºèã®ã¬ãã«ã«ãããŠè¡šé¢åãæå°åã
ããåŒåžãµã€ã¯ã«ãé ããŠèºèãéããç¶æ ã«ä¿
ã€ç¹ã«ãããŠé倧ãªåœ¹å²ãæããŠããããšãåå
ã«èªèãããŠããã è¡šé¢æŽ»æ§å€ã®è¡šé¢ç¹æ§ãå现èäœå€æ¶²ã®è¡æ¶²ã
ã现èäœå€ç©ºéãžã®ç§»åãæžå°ããã圹å²ãæã
ããŠããããšã«ã€ããŠã幟ããã®èšŒæ ããããã
ã®ç¹æ§ã«é¢é£ããŠãæ¬çºæè ã®äžäººã¯è¡šé¢æŽ»æ§å€
ã¯åžè²©ãããŠããç©è³ªè¡šé¢ãåŠçããããã«çšã
ãããæ¥æ°Žå€ãšç°ããçäœçµç¹ãé湿最æ§ãšãã
ããšãæè¿ç«èšŒããããã®äœçšã®èºèã«æ°Žååã
ãã®è¡šé¢ã浞éããã®ã«æµæããçæ°Žæ§ã®å 匵ã
ãäžãããã®ã§ããã æ¬çºæãéæããã«è³ã€ãæè¿ã®å®éšã«ãã
ãŠãæ¬çºæè ãã¯èè žç²èè¡šç®ã®ãªã³è質被èŠã
åæ§ã«ãã®çµç¹ã«çæ°Žæ§è¡šé¢è¢«èŠãäžããå¯èœæ§
ã«ã€ããŠèæ ®ãããããããã§ããã°ãããã¯ã
ã®æ®ãã©ãæ°Žæ§æº¶æ¶²äžã«æº¶è§£ããŠãã管è å ã®å·
害ç©è³ªãäœæ ç²èè¡šç®ã«æµžéããªããã説æãã
ããšãã§ãããåŸã€ãŠãéå£ã®å ã®ãŸãŸã®ç¶æ ã
æ¬åœã«èè žæœ°ççºçã«ãããäž»ããæ¬ é¥ã§ãããª
ãã°ãéžã°ããæ²»çæ³ã¯è¡šé¢éå£ã®èœåãå埩ã
ãè¬åãæäžããããšã§ãããæ¬çºæã¯ãèè žæœ°
çæ§è é£ã修埩ããäºé²ããã®ã«æå¹ãªãã®æ§ãª
çµæç©ããã³æ²»çæ¹æ³ãéçºããããšãæ¢çŽ¢ãã
ãã®ã§ããã çºæã®èŠçŽ æ¬çºæã«ããã°ããªã³è質ååç©ãèè žæœ°ç眹
æ£æ§æ£è ã«å éšæäžã«é©ãã圢æ ã§å«ãããšãç¹
城ãšããèè žæœ°çç ã®æ²»ççšçµæç©ãæäŸãã
ããäžè¬çã«ãæ¬çºæã«ããã°ããããªã³è質å
åç©ãåç¬ã§æãã¯ãã®ä»ã®ãªã³è質ååç©ãšäž
ç·ã«çµåããããŠè¬åŠçã«èš±å®¹å¯èœãªæäžåœ¢æ ã«
ãããŠèè žæœ°ç眹æ£æ§æ£è ã«çµå£çã«æäžãã
ãããã®ãªã³è質衚é¢æŽ»æ§å€çµæç©ã¯ãç²èè¡šé¢
ã被èŠããããã«ããç²â挿èãéããŠã®é žæµã
é²æ¢ããã«ååãªçæ°Žæ§éå£ã圢æããã®ã«æå¹
ã§ããã ãã€ãŠãæ¬çºæã¯ãªã³è質衚é¢æŽ»æ§å€ãå«ãæ
朰çå»è¬çµæç©ãæäŸããã æŽã«ãæ¬çºæã«ããã°ãèè žæœ°çã®æ²»çã«æå¹
ãªäž¡æ§ããã³ã¢ããªã³æ§ãªã³è質衚é¢æŽ»æ§å€ã®äž¡
è ãå«ãæ朰çå»è¬çµæç©ãæäŸããããäž¡æ§ãª
ã³è質çµæç©ã«ã¢ããªã³æ§ãªã³è質衚é¢æŽ»æ§å€ã
å å«ãããããšã«ããããªã³è質ã®ç²èè¡šé¢äžãž
ã®æ²ç©é床ãé«ããããããã«æãããã 奜ãŸããå®æœæ æ§ã®å ·äœçãªèª¬æ 以äžãæ¬çºæãæ¬åºé¡æç¹ã«ãããŠæè¯ã®æ æ§
ãè¡šãããã®ãšæããã奜ãŸããå®æœæ æ§ã«åã
ãŠèª¬æããã ãã®æ§ãªæ¬çºæã®å¥œãŸããå®æœæ æ§ã«ããã°ã
ãªã³è質衚é¢æŽ»æ§å€çµæç©ã¯èè žæœ°çç ã®æå¹ãª
æ²»çãšããŠæäŸããããèè žæœ°çç ãšããŠã¯ãäŸ
ãã°æ¶åæ§æœ°çãè朰çãåäºæè žæœ°çãç©ºè žæœ°
çãé£é朰çãããã³å£æ»æ§å šè žçãªã©ãæãã
ãããããããã«éå®ããããã®ã§ã¯ãªãã æ¬çºæã«ãããæ¹æ³ã«ããã°ãæå¹éã®ãªã³è
質衚é¢æŽ»æ§å€ãå«æããçµæç©ãèè žæœ°çã«ãã
ã€ãŠããæãã¯ããããããæ£è ã«æäžãããã
ã®çµæç©ã¯åŒç¶ããããèè žæœ°çåãç·©åããã²
é²æ¢ãããæ¬çºæã®äž¡æ§ãªã³è質衚é¢æŽ»æ§å€ã¯ã
ã«ããªã³æ§é»è·ã圢æããããšã®ã§ããæ«ç«¯å®èœ
åºã瀺ããã¹ãã眮æåºãæããé·éèèªæäºçœ®
æãã¹ãã°ãªã»ããŒã«åååç©ãå å«ãããã®ã§
ãããæ¬çºæã®çµæç©ã®è¬åŠçã«æŽ»æ§ãªæåã¯ã
äžè¬ççš®é¡ãšããŠãªã³è質é¡ãå³ã¡ãã¬ã·ãã³ã
ã±ãã¢ãªã³ãã¹ãã€ã³ãŽããšãªã³ããã¹ãã¢ããž
ã«ã°ãªã»ããŒã«ããã¹ãã¢ããžã«ã»ãªã³ããã³ã
ã¹ãã¢ããžã«ã€ãã·ããŒã«ãªã©ãå«ããã®ã§ã
ãã äžèšã®äžè¬åŒã¯æ¬çºæã®çµæç©ããã³æ¬çºæã«
ãããæ¹æ³ã«å å«ããããªã³è質é¡ã®äžè¬æ§é åŒ
ãè¡šãããã®ã®ä»£è¡šäŸã§ãããããããã«éãã
ããã®ã§ã¯ãªãïŒ
ããç¹ã«æ¬çºæã¯èè žæœ°çç ã®æ²»çããã³äºé²ã«
æçšãªãªã³è質衚é¢æŽ»æ§å€çµæç©ã«é¢ããã èè žæœ°çç ãç¹ã«æ¶åæ§æœ°çã¯ç±³åœäººå£ã®ïŒã
15ïŒ ãåããŠããã®ã§ãããæŽã«ããã®ç æ°ã¯ã
ãå·¥æ¥åããã西æŽæåã«éããããã®ã§ã¯ãª
ããäºå®ãè朰çã¯ãããæ±æŽã«ãããŠæŽã«æ·±å»
ãªåé¡ã§ãããäžã€ã®ç¹ã«å°å ç§å»ã«ããã©ããª
朰çç ã¯ãæªçãªå¹Œå ã«çºçããŠããããã®å£æ»
æ§å šè žçãšããŠç¥ãããŠããç æ ã¯1.5Kgæªæºã®
åºç£äœéãæããæ°çå ã®10ã15ïŒ ãåããã®ã§
ããããã°ãã°å€ç§æè¡ãå¿ èŠãšãããããªéã
çŽè žæœ°çãããããã®ã§ããããã®ç æ ã®åå ã¯
æ¶åæ§æœ°çãšåæ§ã«ããã€ãŠããªããããããã
äž»ããæ¬ é¥ã¯ç®¡è å·å®³å€ã«å¯Ÿããç°åžžãªç²èé²åŸ¡
æ©æ§ã«ååšãããã®ãšèããããŠããã çŸåšãåžå Žã«ã¯å€ãã®æ朰çå±åãããããã
ãã®è¬åã®æ®ãã©ã¯ãèé žåæ³ã®äžåæãã¯æå¶
ã«åãããããã®ã§ãããæ朰ççµæç©ã®èåãª
ãã®ãšããŠã¯ãæã³ãªã³äœçšå€ããã³æãã¹ã¿ã
ã³å€ããããããããã®äž¡è ã¯éæ¥çæ²»çæ段ã§
ãããèé žåæ³ã®åŠšå®³ã«å ããŠãå€ãã®æãŸãã
ãªãå¯äœçšãçããããã®æ²»ç圢æ ã¯ãé žãªãã
ã°æœ°çãªãããšãã䞻矩ã«åºã¥ããŠããã朰çã¯
èé žã®å®å šãªäžååšäžã«ãããŠã¯åœ¢æããªããã
ã«æãããããå¿ ãããå šãŠã®æœ°çæ£è ãé«ãã
ããèé žåæ³ã瀺ããšã¯éããªãããšãäžè¬çã«
èªèãããŠãããäºå®ããã矀ã®è朰çæ£è ã¯ç°
åžžã«äœãèé žæ§ãæããããã®æ§ã«ãèé žæ§ã¯å
ãªãæªåèŠå ã«ããããèè žæœ°ççºçã®äž»ããå
å ã§ã¯ãªãããšã瀺åãããŠããã 朰ççºçã®å¥ã®èª¬æãšããŠã¯ãèè žæœ°çã¯æ³å
äžã®ãèç²èéå£ãã«æ¬ é¥ãæããå人ã«çºå±ã
ããšä¿¡å¿µãå«ããã®ã§ããããã®æ¬ é¥ãšããŠã¯ã
管è å·å®³å€ïŒé žãé µçŽ ãèæ±å¡©ããã¯ããªã¢ïŒã
è¡šé¢èã«æµžéããããã®åŸæœ°çãä¿é²ãããããš
ã§ããã çŸåšã®ãšãããæ£åžžã®èè žïŒGIïŒè¡šç®ããã
èªäœåŠäœã«ããŠãããã®æ»æããå®ããã«ã€ããŠ
ã¯äžæã§ããã確ãã«ããã®åºæ¬ççåã«å¯Ÿãã
解çãé·ãæ¢çŽ¢ãããŠããŠããããšããã®ã¯ãè
ãåžžã«æ¥µç«¯ã«é žæ§ã®èçœè³ªå解æ§ç°å¢ã«æµŽããªã
ããäœæ èãããèªèº«ãæ¶åããªãã®ããšããé
説ãäŸç¶ç¢ºãã«æ®ããã®ã§ããããã§ãããå察
ã«ã朰çç ããã³å£æ»æ§å šè žçã«ãããŠåŠäœã«ã
ãŠåäœæ ã«ãã®ä¿è·èŠçŽ ãé€å»ããåã¯éããã
ãããŠããŸãã®ããšããããšã«ã€ããŠã®èšåºçã«
éèŠãªåé¡ãæ®ã€ãŠããããããã®éèŠãªåé¡ã«
察ããŠè§£çãäžããããã«ã極ããŠå€ãã®ç 究ã
è¡ãããŠãããç 究è éã¯ç²èããå¡©é žãã®ä»ã®
æœåšçã«æ¯æ§ç©è³ªã®ç®¡è ããè¡šç®ãžã®éæ¡æ£ãé²
æ¢ããæ³åäžã®ãèè žç²èéå£ãã«ããä¿è·ãã
ãŠãããšä»®å®ããŠããããã®ç²èéå£ã®ç Žå£ã®çµ
æãèè žè é£ãé²å±ãããäŸãã°ãã¢ã¹ããªã³ã
èæ±å¡©ãå¡©é žããã³ã¢ã«ã³ãŒã«ãªã©ã®åºç¯å²ã®å·
害ç©è³ªãååãªé«æ¿åºŠã§ååšããã°èè žæœ°çåã
確ãã«çãããããã®ã§ããããããã倧å€æ°ã®
æ£è ã«ããã朰çç ã®äž»ããåå ã¯ããèè žç²è
éå£ãã®çæ¥ã®æ¬ é¥ã«åž°ãããããã®ãšäžè¬çã«
æãããŠããã æ¬çºæè çã«ããæè¿ã®ç 究ã®ç€ºããšããã«ã
ãã°ãèºæ¶²ã«ååšããå€ãã®ãªã³è質ãé£éãã
çµè žã«è³ãèè žç®¡ã®é·ãã«æ²¿ã€ãŠãååšããããš
ãå€æããããããã®ãªã³è質ã¯ãæ¶åæ§ããã³
åžåæ§è¡šç®ã管è å 容ç©ããåé¢ããçµç¹ã®ç²è
è¡šé¢äžã«éäžããŠããããã§ããããããã®åå
ç©ã®æ©èœçéèŠæ§ã¯èºã«ãããŠæã詳现ã«ç 究ã
ããŠæ¥ãŠãããã®ã§ãããçŸåšã§ã¯ãèºã®è¡šé¢æŽ»
æ§å€ã¯èºèã®ã¬ãã«ã«ãããŠè¡šé¢åãæå°åã
ããåŒåžãµã€ã¯ã«ãé ããŠèºèãéããç¶æ ã«ä¿
ã€ç¹ã«ãããŠé倧ãªåœ¹å²ãæããŠããããšãåå
ã«èªèãããŠããã è¡šé¢æŽ»æ§å€ã®è¡šé¢ç¹æ§ãå现èäœå€æ¶²ã®è¡æ¶²ã
ã现èäœå€ç©ºéãžã®ç§»åãæžå°ããã圹å²ãæã
ããŠããããšã«ã€ããŠã幟ããã®èšŒæ ããããã
ã®ç¹æ§ã«é¢é£ããŠãæ¬çºæè ã®äžäººã¯è¡šé¢æŽ»æ§å€
ã¯åžè²©ãããŠããç©è³ªè¡šé¢ãåŠçããããã«çšã
ãããæ¥æ°Žå€ãšç°ããçäœçµç¹ãé湿最æ§ãšãã
ããšãæè¿ç«èšŒããããã®äœçšã®èºèã«æ°Žååã
ãã®è¡šé¢ã浞éããã®ã«æµæããçæ°Žæ§ã®å 匵ã
ãäžãããã®ã§ããã æ¬çºæãéæããã«è³ã€ãæè¿ã®å®éšã«ãã
ãŠãæ¬çºæè ãã¯èè žç²èè¡šç®ã®ãªã³è質被èŠã
åæ§ã«ãã®çµç¹ã«çæ°Žæ§è¡šé¢è¢«èŠãäžããå¯èœæ§
ã«ã€ããŠèæ ®ãããããããã§ããã°ãããã¯ã
ã®æ®ãã©ãæ°Žæ§æº¶æ¶²äžã«æº¶è§£ããŠãã管è å ã®å·
害ç©è³ªãäœæ ç²èè¡šç®ã«æµžéããªããã説æãã
ããšãã§ãããåŸã€ãŠãéå£ã®å ã®ãŸãŸã®ç¶æ ã
æ¬åœã«èè žæœ°ççºçã«ãããäž»ããæ¬ é¥ã§ãããª
ãã°ãéžã°ããæ²»çæ³ã¯è¡šé¢éå£ã®èœåãå埩ã
ãè¬åãæäžããããšã§ãããæ¬çºæã¯ãèè žæœ°
çæ§è é£ã修埩ããäºé²ããã®ã«æå¹ãªãã®æ§ãª
çµæç©ããã³æ²»çæ¹æ³ãéçºããããšãæ¢çŽ¢ãã
ãã®ã§ããã çºæã®èŠçŽ æ¬çºæã«ããã°ããªã³è質ååç©ãèè žæœ°ç眹
æ£æ§æ£è ã«å éšæäžã«é©ãã圢æ ã§å«ãããšãç¹
城ãšããèè žæœ°çç ã®æ²»ççšçµæç©ãæäŸãã
ããäžè¬çã«ãæ¬çºæã«ããã°ããããªã³è質å
åç©ãåç¬ã§æãã¯ãã®ä»ã®ãªã³è質ååç©ãšäž
ç·ã«çµåããããŠè¬åŠçã«èš±å®¹å¯èœãªæäžåœ¢æ ã«
ãããŠèè žæœ°ç眹æ£æ§æ£è ã«çµå£çã«æäžãã
ãããã®ãªã³è質衚é¢æŽ»æ§å€çµæç©ã¯ãç²èè¡šé¢
ã被èŠããããã«ããç²â挿èãéããŠã®é žæµã
é²æ¢ããã«ååãªçæ°Žæ§éå£ã圢æããã®ã«æå¹
ã§ããã ãã€ãŠãæ¬çºæã¯ãªã³è質衚é¢æŽ»æ§å€ãå«ãæ
朰çå»è¬çµæç©ãæäŸããã æŽã«ãæ¬çºæã«ããã°ãèè žæœ°çã®æ²»çã«æå¹
ãªäž¡æ§ããã³ã¢ããªã³æ§ãªã³è質衚é¢æŽ»æ§å€ã®äž¡
è ãå«ãæ朰çå»è¬çµæç©ãæäŸããããäž¡æ§ãª
ã³è質çµæç©ã«ã¢ããªã³æ§ãªã³è質衚é¢æŽ»æ§å€ã
å å«ãããããšã«ããããªã³è質ã®ç²èè¡šé¢äžãž
ã®æ²ç©é床ãé«ããããããã«æãããã 奜ãŸããå®æœæ æ§ã®å ·äœçãªèª¬æ 以äžãæ¬çºæãæ¬åºé¡æç¹ã«ãããŠæè¯ã®æ æ§
ãè¡šãããã®ãšæããã奜ãŸããå®æœæ æ§ã«åã
ãŠèª¬æããã ãã®æ§ãªæ¬çºæã®å¥œãŸããå®æœæ æ§ã«ããã°ã
ãªã³è質衚é¢æŽ»æ§å€çµæç©ã¯èè žæœ°çç ã®æå¹ãª
æ²»çãšããŠæäŸããããèè žæœ°çç ãšããŠã¯ãäŸ
ãã°æ¶åæ§æœ°çãè朰çãåäºæè žæœ°çãç©ºè žæœ°
çãé£é朰çãããã³å£æ»æ§å šè žçãªã©ãæãã
ãããããããã«éå®ããããã®ã§ã¯ãªãã æ¬çºæã«ãããæ¹æ³ã«ããã°ãæå¹éã®ãªã³è
質衚é¢æŽ»æ§å€ãå«æããçµæç©ãèè žæœ°çã«ãã
ã€ãŠããæãã¯ããããããæ£è ã«æäžãããã
ã®çµæç©ã¯åŒç¶ããããèè žæœ°çåãç·©åããã²
é²æ¢ãããæ¬çºæã®äž¡æ§ãªã³è質衚é¢æŽ»æ§å€ã¯ã
ã«ããªã³æ§é»è·ã圢æããããšã®ã§ããæ«ç«¯å®èœ
åºã瀺ããã¹ãã眮æåºãæããé·éèèªæäºçœ®
æãã¹ãã°ãªã»ããŒã«åååç©ãå å«ãããã®ã§
ãããæ¬çºæã®çµæç©ã®è¬åŠçã«æŽ»æ§ãªæåã¯ã
äžè¬ççš®é¡ãšããŠãªã³è質é¡ãå³ã¡ãã¬ã·ãã³ã
ã±ãã¢ãªã³ãã¹ãã€ã³ãŽããšãªã³ããã¹ãã¢ããž
ã«ã°ãªã»ããŒã«ããã¹ãã¢ããžã«ã»ãªã³ããã³ã
ã¹ãã¢ããžã«ã€ãã·ããŒã«ãªã©ãå«ããã®ã§ã
ãã äžèšã®äžè¬åŒã¯æ¬çºæã®çµæç©ããã³æ¬çºæã«
ãããæ¹æ³ã«å å«ããããªã³è質é¡ã®äžè¬æ§é åŒ
ãè¡šãããã®ã®ä»£è¡šäŸã§ãããããããã«éãã
ããã®ã§ã¯ãªãïŒ
ãåŒã
 ãã¹ãã¢ããžã«ãšã¿ããŒã«ã¢ãã³ïŒã±ãã¢ãª
ã³ïŒïŒ
ã³ïŒïŒ
ãåŒã
 ãã¹ãã¢ããžã«ã¢ãã¡ãã«ãšã¿ããŒã«ã¢ã
ã³ïŒ
ã³ïŒ
ãåã
 ãã¹ãã¢ããžã«ãžã¡ãã«ãšã¿ããŒã«ã¢ãã³ïŒ
ããã³
ããã³
ãåã
 ãã¹ãã¢ããžã«ã³ãªã³ïŒ
äžèšåŒäžãR1ããã³R2ã¯åã
ç¬ç«ã«é£œåå
ã¯äžé£œåã®ïŒã21ã®ççŽ æ°ãé©åœã«ã¯13ã21ã®
ççŽ æ°ã奜ãŸããã¯13ã17ã®ççŽ æ°ãæããè
èªæåºãè¡šããã
ã¯äžé£œåã®ïŒã21ã®ççŽ æ°ãé©åœã«ã¯13ã21ã®
ççŽ æ°ã奜ãŸããã¯13ã17ã®ççŽ æ°ãæããè
èªæåºãè¡šããã
ãåŒã
 ãã¹ãã¢ããžã«ã»ãªã³
æŽã«ãæ¬çºæã®çµæç©ã«ããã°ãäžèšäžè¬åŒ
ãæããã¢ããªã³æ§ãªã³è質ãäžèšäž¡æ§ãªã³è
質衚é¢æŽ»æ§å€ã®äžçš®ä»¥äžãšçµåããæå¹ã«ãªã³
è質ã®è¡šé¢æ²ç©ããã³æ朰ç掻æ§ãå éããã³
ä¿é²ããããšãã§ããïŒ
ãæããã¢ããªã³æ§ãªã³è質ãäžèšäž¡æ§ãªã³è
質衚é¢æŽ»æ§å€ã®äžçš®ä»¥äžãšçµåããæå¹ã«ãªã³
è質ã®è¡šé¢æ²ç©ããã³æ朰ç掻æ§ãå éããã³
ä¿é²ããããšãã§ããïŒ
ãåŒã
 ãã¹ãã¢ããžã«ã°ãªã»ããŒã«
ãåã
 ãã¹ãã¢ããžã«ã€ãã·ããŒã«
åŒäžãR1ããã³R2ã¯åã
ç¬ç«ã«é£œååã¯äž
飜åã®ïŒã21ã®ççŽ æ°ãé©åœã«ã¯13ã21ã®ççŽ
æ°ã奜ãŸããã¯13ã17ã®ççŽ æ°ãæããèèªæ
åºãè¡šããã ç¹ã«ãå ·äœçãªååç©ãšããŠã¯ããžãã«ããã€
ã«ã¬ã·ãã³ïŒDPLïŒããžãã«ããã€ãã¹ãã¢ããž
ãšã¿ããŒã«ã¢ãã³ïŒDPPEïŒãã¹ãã€ã³ãŽããšãª
ã³ïŒSphgïŒããã³ãžãã«ããã€ã«ãã¹ãã¢ããž
ã«ã»ãªã³ïŒDPPSïŒãæ¬çºæãå®æœããã®ã«æå¹
ãªå¥œãŸããäž¡æ§ãªã³è質衚é¢æŽ»æ§å€ã§ãããåã
ãžãã«ããã€ã«ãã¹ãã¢ããžã«ã°ãªã»ããŒã«
ïŒDPPGïŒããã³ãžãã«ããã€ã«ãã¹ãã¢ããžã«
ã€ãã·ããŒã«ïŒDPPIïŒãäž¡æ§ãªã³è質é¡ã®äžçš®
以äžãšçµåããŠäœ¿çšããã奜ãŸããã¢ããªã³æ§è¡š
é¢æŽ»æ§å€ã§ããã ç¹ã«èã®ç°å¢å ã§ééããé žæ§æ¡ä»¶äžã«ãããŠ
ã¯ãäžèšäž¡æ§ãªã³è質衚é¢æŽ»æ§å€ã¯å žåçã«ã¢ã
ãæ«ç«¯ã«ãããŠæ°ŽçŽ ã€ãªã³ãå容ããããšã«ãã
æ£é»è·ãå³ã¡ãã«ããªã³é»è·ã瀺ãã®ã§ãããã
ã¯æå¹ã«ã«ããªã³æ§ã§ããã æ¬çºæã®äž»é¡ã§ãããªã³è質ã¯ãæ€ç©ããã³å
ç©æºããæœåºå¯èœãªå€©ç¶ç©è³ªã§ãããæŽã«ãäžèš
ãªã³è質ã®å€ãã¯åçš®å ¬ç¥æ¹æ³ã«ãã調補ããã
ãšãã§ãããæŽã«ãå€ãã®ãªã³è質ã¯åçš®ç³ã
ããå»è¬èª¿å€ããã³çååŠç 究ææã®åºçºææã§
ããã®ã§åžè²©ãããŠããã æ¬çºæã«ãããæ¹æ³ã¯ããããã®ååç©ã®èè ž
朰çã®æ²»çããã³é²æ¢ãžã®çšéã«åãããããã®
ã§ããããã®æ¹æ³ã¯æ£è ã«äžçš®ä»¥äžã®ãªã³è質ã
è¬åŠçã«æå¹éã«ãŠå éšçã«æäžããããšãç¹åŸŽ
ãšãããã®ã§ããã奜ãŸããæäžçµè·¯ã¯ãçµå£æ
äžã§ãããã錻è å ã¹ãã¬ãŒã®ãããªãã®ä»ã®çµ
è·¯ãå䜿çšããããšãã§ãããããããªãããæ
äžçµè·¯ã¯æœ°çã«ããããããæãã¯ããã€ãŠãã
ç²èå±€äžã«ãªã³è質衚é¢æŽ»æ§å€ã®ååãªè¢«èŠã®æ²
ç©ãå¯èœããã«çµè·¯ã«éãããã çµå£æäžã®ããã«ã¯ãååç©ãå®è³ªçã«çŽç²ãª
æªçšé圢æ ã§æäžããããšãã§ããæãã¯åçš®å»
è¬æäžåœ¢æ ãäŸãã°ã«ãã»ã«ããªããŸãŒã æ äœã
ãšã¢ããŸãŒã«ã¹ãã¬ãŒãåæ£æ¶²ãæ°Žæ§æžæ¿æ¶²ã溶
液ãªã©ã®åœ¢æ ã§æäžããããšãã§ããã 以äžã®çè«ã«å¶çŽãåããæå³ãæãããã®ã§
ã¯ãªãããæ¬çºæã¯æ£ã®æ«ç«¯é»è·ãæããè¡šé¢æŽ»
æ§å€ãèè žçµè·¯ã®è² ã«è·é»ããè¡šé¢èã«åžåŒãã
ããšããåçã«åºã¥ããã®ã§ããããããã®åå
ã¯æ¬¡ãã§ãããã®é·ãçåæ°ŽçŽ éã管è äžã«å€æ¹
ã«å»¶åšããããã«é åããïŒç¬¬ïŒå³åç §ïŒããã®
çµæãçµç¹ãèŠã€ãŠåäžãªçæ°Žæ§å±€ã圢æããã
ããã¯èŠªæ°Žæ§å·å®³ç©è³ªã«ãã浞éãããªãããã
ã¯ã氎溶æ§å·å®³ç©è³ªïŒäŸãé žã埮çç©æ¯ç©ãèçœ
質åè§£é µçŽ ïŒãçµç¹ãšæ¥è§Šããã®ãé²æ¢ããçµç¹
ãæå·ããä¿è·ããã ã¢ããªã³æ§è¡šé¢æŽ»æ§åšã¯è² ã«åž¯é»ããè¡šé¢å 匵
ãã«ããææ¥ããïŒåŸã€ãŠä¿è·å·å®³ãäžããã«æ
å¹ã§ãªãïŒããšãäºæ³ãããããããããæ¬çºæ
ã®çµæç©ã«ã¢ããªã³æ§çé¢æŽ»æ§å€ãå«ãŸããããš
ã¯å¥œãŸããå®æœæ æ§ã®äžã€ã§ãããäžã€ã®å¯èœæ§
ã®ãã説æãæãããšãã¢ããªã³æ§ãªã³è質ãäž¡
æ§ãªã³è質ã®æžæ¿æ¶²ã«æ·»å ãããšããããã®è¡šé¢
掻æ§å€ã®æžæ¿æ¶²ããã®æåºãå éããããšãå€æ
ãããå³ã¡ãã¢ããªã³æ§ãªã³è質ãå«æãããªã³
è質æžæ¿æ¶²ã¯ã¢ããªã³æ§ãªã³è質ãååšããªãå Ž
åã«æ¯ã¹ãŠããè¿ éãªé床ã§çäœè¡šé¢ã被èŠã
ãã æ¬çºæã®å®æœã«éããåææãã¯å€©ç¶ã®ãªã³è
質ã§äºååŠçãããèã®ç²èã¯å®è³ªçã«é žã«å¯Ÿã
ãŠäžæµžéæ§ãšãªãããšãèŠåºãããããã®ç¹æ§ã¯
in vivoã«ãããŠæãåçã«ç€ºããããªã³è質ã§
åŠçãããã©ããã¯åŒ·ãå¡©é žæº¶æ¶²ã«çŽæ¥è² è·ãã
ãåŸã«æ¿ããèã®ç²èæå·ã«æµæã瀺ãããšã芳
å¯ããããå¯Ÿç §çã«ãå¡©æ°ŽåŠçãããã©ããã¯æ¿
ããèã®è é£ããã³åºè¡ã被ã€ããin vitroã®èŒª
éç 究ã¯ãããã®ç¥èŠã確èªãã管è ãªã³è質衚
é¢æŽ»æ§å€ã«æãããèã®ç²èãééããé žïŒH+ïŒ
ã®æ¡æ£é床ã¯æªåŠççµç¹ãééããé床ããã¯ã
ãã«é ãããšã瀺ãã æ¬çºæãããæ確ã«ç解ãããããã«ä»¥äžã«å ·
äœäŸã«åããŠå¥œãŸããå®æœæ æ§ãæŽã«è©³çŽ°ã«èª¬æ
ãããããããã¯æ¬çºæã®ç¯å²ãéå®ãããã®ã§
ã¯ãªãã äŸ H+éæ¡æ£ã«å¯Ÿãããªã³è質ä¿è·ã®in vitroç
究 ãã®å®éšã¯ãã€ãã®èã®ç²èã®è¡šé¢ã«åžçãã
ããªã³è質ãæå¹ã«ã€ãã®èã®ç²èãééãã
H+ã®ç²èãã挿èã«è³ãæµããé ãããããšã
ã§ãããã©ããã決å®ããããã«è¡ããããã®ã§
ãããåŸã€ãŠã麻é ããããã€ãã®é žæ§ç©åæ³è º
ã®èç²èã®äºã€ã®é£æ¥çããã®äžã«ãã挿èãã
åŒãå¥ããä¿®æ£ãããUssing Chamber
ãShanbourã«ããAmerican Journal of
Digestive Diseases 19ïŒ397ã371ïŒ1974ïŒã«èš
èŒãã«å ¥ããã15mlãã€ã®é žçŽ åŠçãããèŠå®å¡©
æ°Žãç²èããã³äž¡æ¹ã®è³ªã®æ é€åºç»å®€ã«æ·»å ãã
çµç¹ã¯ç 究ã®éé£ç¶çã«é žçŽ åŠçããã åæã®ç 究ã«ãããŠã¯ã50ÎŒïœã®æ¬¡ã®ãªã³è
質ãå³ã¡ããžãã«ããã€ã«ã¬ã·ãã³ïŒDPLïŒããž
ãã«ããã€ã«ãã¹ãã¢ããžã«ãšã¿ããŒã«ã¢ãã³
ïŒDPPEïŒããžãã«ããã€ã«ãã¹ãã¢ããžã«ã°ãªã»
ããŒã«ïŒDPPGïŒããžãã«ããã€ã«ãã¹ãã¢ããž
ã«ã€ãã·ããŒã«ïŒDPPIïŒããã³ã¹ãã³ãŽããšãª
ã³ãååæžæ¿æ¶²ãšããŠå®€ã®äžæ¹ã®ç²èåºç»å®€ã®èŠ
å®å¡©æº¶æ¶²ã«æ·»å ãããåæäºæž¬ã«åŸãã°ãã®ç³»ã«
æ·»å ããå šãªã³è質æ¿åºŠïŒ250ÎŒïœïŒã¯ãäºãå®
ããããé¢ç©ã®èã®ç²èè¡šé¢ã«åžçããããªã³è
質ã®å šéãšã»ãŒçããã€ããè©Šéšããããªã³è質
ã®åã ã¯Sigma Chemical瀟ïŒSt.Louisã
MissouriïŒããåŸããããã®ã§ãã€ãã åããªã³è質ã®æ·»å ã¯ïŒãïŒã®ç¯å²ã®ç²èã浞
ã溶液ã®PHã«äœçã®åœ±é¿ãåãŒããªãããšãå€æ
ãããPHèšã®é»æ°åºåã¯ïŒãã€ã³ãã«Bekcman
DynographïŒType R411ïŒã«æ¥ç¶ããã挿液äžã®
PHå€åã¯æéãšå ±ã«ç£èŠããããäžåºŠå®å®ãªåºæº
ç·ã«å°éãããšãå·å®³æ¿åºŠã®HClïŒ900ïœïŒïŒãç²
è宀ã«æ·»å ãããäžã€ã®å®éšã«ãããŠãå¯Ÿç §å®€ã®
挿è溶液ã®PHã¯H+ã宀ã®æŒ¿èåŽã«æµžéããåã«
å¹³å2.40åéå®å®ã§ãã€ãããªã³è質被èŠç²èã«
é¢ããŠãH+浞éã®å¹³åç Žå£ç¹ã¯6.70åã«å»¶é·ã
ãããæŽã«ç Žå£ç¹åŸã®H+æµã®é床ã¯ãªã³è質詊
æã®å Žåã«ã¯æªåŠçå¯Ÿç §äŸã®å Žåã®ããã«ã¯éã
ãªãã€ããããã¯ç 究ããåŸãããåŸæããæã
ãã§ããïŒç¬¬ïŒå³åç §ïŒã 第äºçªç®ã®äžé£ã®å®éšã«ãããŠã¯ãç²è質ã«æ·»
å ããåã ã®è¡šé¢æŽ»æ§å€ã®çžå¯Ÿæ¿åºŠããªã³è質ã®
å šéãäœãå€ããããšãªãå€åãããããããã®
å®éšã«ãããŠã¯ã135ÎŒïœã®DPLãåã 15ÎŒïœã®æ¬¡
ã®ãªã³è質ãå³ã¡ãPEãPGãPIããã³ã¹ãã€ã³
ãŽããšãªã³ãšå ±ã«æ·»å ãããæŽã«ãããã®å®éšã«
ãããŠãªã³è質æžæ¿æ¶²ãåºç»å®€ã«æ·»å ããããã®
çµæããªããŸãŒã ã®ç²åã圢æãããããããã®
ä¿®æ£ã«ããH+æµã挿èåŽã«èŠãããåã«æŽã«ç Ž
å£ç¹ã10.0åã«ãŸã§å»¶é·ããã äŸ ãªã³è質ä¿è·ã®in vivoç 究 åè¿°ã®å®éšã«ãããŠãæ¬çºæè çã¯èã®ç²èè¡š
é¢ã®in vitroã§ã®ãªã³è質ã®åŠçã¯ç²èè¡šç®ãé
éããŠç®¡è ããæ é€æµžæŒ¬æº¶æ¶²ãžã®H+ãæ¡æ£ãã
é床ãçžåœã«é 延ãããããšã瀺ãããåŸã€ãŠã
ãããã®çµæã¯ãªã³è質ãH+ã®ç®¡è ããçµç¹ãž
ã®é浞éãé ãããããšã«ããé žâèªçºèè é£ã«
察ããŠä¿è·ãè¡ãããšã瀺åãããæ¬çºæè çã¯
ãã®åé¡ãè©Šéšè©Šè¬ãé£éã«ããŠãŒã¬ã«ããçŽæ¥
èã®äžã«æäžããããšã®ã§ããæ¥æ§å¹œéçµçŽ®ã©ã
ãã«ãããŠæ€èšãããã©ããã¯äžæ©æé£ãããè©Š
éšæéã®éNembutal麻é äžã«ããããã©ããã¯
äºçŸ€ïŒïŒå¹ïŒçŸ€ïŒã«åãããè¡šé¢æŽ»æ§å€åŠçããš
称ãããäžæ¹ã®çŸ€ã¯æ¬¡ã®ãªã³è質ïŒ135ÎŒïœDPLã
15ÎŒïœã®DPPEãDPPGãDPPIããã³ã¹ãã€ã³ãŽ
ããšãªã³ã®å¡©æ°Žäžã®ãªããŸãŒã æžæ¿æ¶²0.5mlãå
ãåãã第äºã®çŸ€ïŒå¯Ÿç §äŸïŒã¯0.5mlã®å¡©æ°Žãè
ã®äžã«æ³šå°ãããïŒååŸã«äž¡çŸ€å ±ã«ïŒmlã®æœ°ççº
çæäžéã®0.6NHClãäžããããã麻é ããã
ãããåç©ã¯éªéãããã«45åéæŸçœ®ããããã®
åŸãããã¯æ®ºãããèãåé€ãã倧åœã«æ²¿ã€ãŠå
ãéãæ€æ»ãããæªåŠçå¯Ÿç §ã©ããã®æœ°ççºçå€
芳ãšã¯å¯Ÿç §çã«è¡šé¢æŽ»æ§å€ã§äºååŠçããã©ãã
ã¯å šäœçã«æ®ãã©æãã¯å šãé žèªçºæå·ãæããª
ãããã«èŠãããã ããäžã€ã®äžé£ã®in vivoå®éšã«ãããŠãåã
ã®ãªã³è質å³ã¡ãžãã«ããã€ã«ã¬ã·ãã³ããžãã«
ããã«ãã¹ãã¢ããžã«ãšã¿ããŒã«ã¢ãã³ãããã³
ãã¹ãã¢ããžã«ã³ãªã³ã®æ朰ç掻æ§ã®è©Šéšãè¡ã€
ããå®éšã¯åè¿°ãšåæ§ã«ããŠè¡ã€ããæŽã«ã©ãã
ã殺ãçŽåã«èã®è©ŠæãæãåºããŠãã¢ã°ããã³
åæãè¡ã€ããè©Šæã«ååšãããã¢ã°ããã³ã®é
ã¯èè žåºè¡ã®çšåºŠã«æ£æ¯äŸããåŸã€ãŠã朰çå掻
æ§ã«æ£æ¯äŸãããè©Šæã®æ朰ç掻æ§ã¯ã135ÎŒïœ
DPLã15ÎŒïœã®DPPEãDPPGãDPPIããã³ã¹ã
ã€ã³ãŽããšãªã³æ··åç©ã®çµåãã§äºååŠçããå
ç©ããæ€åºããããã¢ã°ããã³ã«å¯Ÿãããã¢ã°ã
ãã³ã«ãŠã³ãæ°ã®ããŒã»ã³ããšããŠæž¬å®ãããæ
朰ç掻æ§ã¯æ€åºããããã¢ã°ããã³ã®éã«åæ¯äŸ
ãããè¡šã¯åã ã®è©Šéšããããªã³è質ã®çžå¯Ÿç
æ朰ç掻æ§ã衚瀺ãããã®ã§ããã è¡š ãªã³è質 æŽ»æ§ æ··åç©ïŒ135ÎŒïœDPLãå15ÎŒïœã®DPPEãDPPGã
DPPIããã³Sph.ïŒ 100ïŒ ãžãã«ããã€ã«ã¬ã·ãã³ 15ÎŒïœ 95ïŒ 135ÎŒïœ 90ïŒ ãžãã«ããã€ã«ãã¹ãã¢ããžã«ãšã¿ããŒã«ã¢ãã³ 15ÎŒïœ 75â80ïŒ 135ÎŒïœ 70ïŒ ãã¹ãã¢ããžã«ã³ãªã³ 15ÎŒïœ 80ïŒ 135ÎŒïœ 80ïŒ åèšã®æ¬çºæã®é瀺å 容ã¯ã説æããã³äŸç€ºã®
ç®çã®ããã«ç¹å¥ã®å®æœæ æ§ã«åãããããã®ã§
ãããããããªããã説æãããå®æœæ æ§ã®æ¹æ³
ã«ãããŠå€ãã®ä¿®æ£ããã³å€æŽãæ¬çºæã®æ¬è³ªã
ãé¢ããããšãªããªããããããšãåœæ¥è ã«æã
ãã§ããããäŸãã°ãããã®æ£è ã«æäžããããª
ã³è質ã®éã¯å¹Žä»€ãäœéããã³æœ°çã®ç æ ã®çšåºŠ
ã«å¿ããŠå€åãåŸããã®ã§ãããæ¬çºæã®æ瀺å
容ã«äžè²«ããé©åœäžã€æå¹ãªæäžéã決å®ããèœ
åã¯åœæ¥è ã«æããã§ããããæŽã«ãç¹å¥ãªäºæ
ã«å¯Ÿé¢ããæã«èš±å®¹å¯èœãªæäžçµè·¯ã«å皮修æ£ã
è¡ãããšãåœæ¥è ã«ã¯æããã§ããããäŸãã°ã
幌å ã«ãããå£æ»æ§å šè žçã®æ²»çã¯å¹Œå ã®äººå·¥åŠ
æ¹ã«åæãªã³è質衚é¢æŽ»æ§å€ãè£çµŠããããšã«ã
ã容æã«è¡ãããã
飜åã®ïŒã21ã®ççŽ æ°ãé©åœã«ã¯13ã21ã®ççŽ
æ°ã奜ãŸããã¯13ã17ã®ççŽ æ°ãæããèèªæ
åºãè¡šããã ç¹ã«ãå ·äœçãªååç©ãšããŠã¯ããžãã«ããã€
ã«ã¬ã·ãã³ïŒDPLïŒããžãã«ããã€ãã¹ãã¢ããž
ãšã¿ããŒã«ã¢ãã³ïŒDPPEïŒãã¹ãã€ã³ãŽããšãª
ã³ïŒSphgïŒããã³ãžãã«ããã€ã«ãã¹ãã¢ããž
ã«ã»ãªã³ïŒDPPSïŒãæ¬çºæãå®æœããã®ã«æå¹
ãªå¥œãŸããäž¡æ§ãªã³è質衚é¢æŽ»æ§å€ã§ãããåã
ãžãã«ããã€ã«ãã¹ãã¢ããžã«ã°ãªã»ããŒã«
ïŒDPPGïŒããã³ãžãã«ããã€ã«ãã¹ãã¢ããžã«
ã€ãã·ããŒã«ïŒDPPIïŒãäž¡æ§ãªã³è質é¡ã®äžçš®
以äžãšçµåããŠäœ¿çšããã奜ãŸããã¢ããªã³æ§è¡š
é¢æŽ»æ§å€ã§ããã ç¹ã«èã®ç°å¢å ã§ééããé žæ§æ¡ä»¶äžã«ãããŠ
ã¯ãäžèšäž¡æ§ãªã³è質衚é¢æŽ»æ§å€ã¯å žåçã«ã¢ã
ãæ«ç«¯ã«ãããŠæ°ŽçŽ ã€ãªã³ãå容ããããšã«ãã
æ£é»è·ãå³ã¡ãã«ããªã³é»è·ã瀺ãã®ã§ãããã
ã¯æå¹ã«ã«ããªã³æ§ã§ããã æ¬çºæã®äž»é¡ã§ãããªã³è質ã¯ãæ€ç©ããã³å
ç©æºããæœåºå¯èœãªå€©ç¶ç©è³ªã§ãããæŽã«ãäžèš
ãªã³è質ã®å€ãã¯åçš®å ¬ç¥æ¹æ³ã«ãã調補ããã
ãšãã§ãããæŽã«ãå€ãã®ãªã³è質ã¯åçš®ç³ã
ããå»è¬èª¿å€ããã³çååŠç 究ææã®åºçºææã§
ããã®ã§åžè²©ãããŠããã æ¬çºæã«ãããæ¹æ³ã¯ããããã®ååç©ã®èè ž
朰çã®æ²»çããã³é²æ¢ãžã®çšéã«åãããããã®
ã§ããããã®æ¹æ³ã¯æ£è ã«äžçš®ä»¥äžã®ãªã³è質ã
è¬åŠçã«æå¹éã«ãŠå éšçã«æäžããããšãç¹åŸŽ
ãšãããã®ã§ããã奜ãŸããæäžçµè·¯ã¯ãçµå£æ
äžã§ãããã錻è å ã¹ãã¬ãŒã®ãããªãã®ä»ã®çµ
è·¯ãå䜿çšããããšãã§ãããããããªãããæ
äžçµè·¯ã¯æœ°çã«ããããããæãã¯ããã€ãŠãã
ç²èå±€äžã«ãªã³è質衚é¢æŽ»æ§å€ã®ååãªè¢«èŠã®æ²
ç©ãå¯èœããã«çµè·¯ã«éãããã çµå£æäžã®ããã«ã¯ãååç©ãå®è³ªçã«çŽç²ãª
æªçšé圢æ ã§æäžããããšãã§ããæãã¯åçš®å»
è¬æäžåœ¢æ ãäŸãã°ã«ãã»ã«ããªããŸãŒã æ äœã
ãšã¢ããŸãŒã«ã¹ãã¬ãŒãåæ£æ¶²ãæ°Žæ§æžæ¿æ¶²ã溶
液ãªã©ã®åœ¢æ ã§æäžããããšãã§ããã 以äžã®çè«ã«å¶çŽãåããæå³ãæãããã®ã§
ã¯ãªãããæ¬çºæã¯æ£ã®æ«ç«¯é»è·ãæããè¡šé¢æŽ»
æ§å€ãèè žçµè·¯ã®è² ã«è·é»ããè¡šé¢èã«åžåŒãã
ããšããåçã«åºã¥ããã®ã§ããããããã®åå
ã¯æ¬¡ãã§ãããã®é·ãçåæ°ŽçŽ éã管è äžã«å€æ¹
ã«å»¶åšããããã«é åããïŒç¬¬ïŒå³åç §ïŒããã®
çµæãçµç¹ãèŠã€ãŠåäžãªçæ°Žæ§å±€ã圢æããã
ããã¯èŠªæ°Žæ§å·å®³ç©è³ªã«ãã浞éãããªãããã
ã¯ã氎溶æ§å·å®³ç©è³ªïŒäŸãé žã埮çç©æ¯ç©ãèçœ
質åè§£é µçŽ ïŒãçµç¹ãšæ¥è§Šããã®ãé²æ¢ããçµç¹
ãæå·ããä¿è·ããã ã¢ããªã³æ§è¡šé¢æŽ»æ§åšã¯è² ã«åž¯é»ããè¡šé¢å 匵
ãã«ããææ¥ããïŒåŸã€ãŠä¿è·å·å®³ãäžããã«æ
å¹ã§ãªãïŒããšãäºæ³ãããããããããæ¬çºæ
ã®çµæç©ã«ã¢ããªã³æ§çé¢æŽ»æ§å€ãå«ãŸããããš
ã¯å¥œãŸããå®æœæ æ§ã®äžã€ã§ãããäžã€ã®å¯èœæ§
ã®ãã説æãæãããšãã¢ããªã³æ§ãªã³è質ãäž¡
æ§ãªã³è質ã®æžæ¿æ¶²ã«æ·»å ãããšããããã®è¡šé¢
掻æ§å€ã®æžæ¿æ¶²ããã®æåºãå éããããšãå€æ
ãããå³ã¡ãã¢ããªã³æ§ãªã³è質ãå«æãããªã³
è質æžæ¿æ¶²ã¯ã¢ããªã³æ§ãªã³è質ãååšããªãå Ž
åã«æ¯ã¹ãŠããè¿ éãªé床ã§çäœè¡šé¢ã被èŠã
ãã æ¬çºæã®å®æœã«éããåææãã¯å€©ç¶ã®ãªã³è
質ã§äºååŠçãããèã®ç²èã¯å®è³ªçã«é žã«å¯Ÿã
ãŠäžæµžéæ§ãšãªãããšãèŠåºãããããã®ç¹æ§ã¯
in vivoã«ãããŠæãåçã«ç€ºããããªã³è質ã§
åŠçãããã©ããã¯åŒ·ãå¡©é žæº¶æ¶²ã«çŽæ¥è² è·ãã
ãåŸã«æ¿ããèã®ç²èæå·ã«æµæã瀺ãããšã芳
å¯ããããå¯Ÿç §çã«ãå¡©æ°ŽåŠçãããã©ããã¯æ¿
ããèã®è é£ããã³åºè¡ã被ã€ããin vitroã®èŒª
éç 究ã¯ãããã®ç¥èŠã確èªãã管è ãªã³è質衚
é¢æŽ»æ§å€ã«æãããèã®ç²èãééããé žïŒH+ïŒ
ã®æ¡æ£é床ã¯æªåŠççµç¹ãééããé床ããã¯ã
ãã«é ãããšã瀺ãã æ¬çºæãããæ確ã«ç解ãããããã«ä»¥äžã«å ·
äœäŸã«åããŠå¥œãŸããå®æœæ æ§ãæŽã«è©³çŽ°ã«èª¬æ
ãããããããã¯æ¬çºæã®ç¯å²ãéå®ãããã®ã§
ã¯ãªãã äŸ H+éæ¡æ£ã«å¯Ÿãããªã³è質ä¿è·ã®in vitroç
究 ãã®å®éšã¯ãã€ãã®èã®ç²èã®è¡šé¢ã«åžçãã
ããªã³è質ãæå¹ã«ã€ãã®èã®ç²èãééãã
H+ã®ç²èãã挿èã«è³ãæµããé ãããããšã
ã§ãããã©ããã決å®ããããã«è¡ããããã®ã§
ãããåŸã€ãŠã麻é ããããã€ãã®é žæ§ç©åæ³è º
ã®èç²èã®äºã€ã®é£æ¥çããã®äžã«ãã挿èãã
åŒãå¥ããä¿®æ£ãããUssing Chamber
ãShanbourã«ããAmerican Journal of
Digestive Diseases 19ïŒ397ã371ïŒ1974ïŒã«èš
èŒãã«å ¥ããã15mlãã€ã®é žçŽ åŠçãããèŠå®å¡©
æ°Žãç²èããã³äž¡æ¹ã®è³ªã®æ é€åºç»å®€ã«æ·»å ãã
çµç¹ã¯ç 究ã®éé£ç¶çã«é žçŽ åŠçããã åæã®ç 究ã«ãããŠã¯ã50ÎŒïœã®æ¬¡ã®ãªã³è
質ãå³ã¡ããžãã«ããã€ã«ã¬ã·ãã³ïŒDPLïŒããž
ãã«ããã€ã«ãã¹ãã¢ããžã«ãšã¿ããŒã«ã¢ãã³
ïŒDPPEïŒããžãã«ããã€ã«ãã¹ãã¢ããžã«ã°ãªã»
ããŒã«ïŒDPPGïŒããžãã«ããã€ã«ãã¹ãã¢ããž
ã«ã€ãã·ããŒã«ïŒDPPIïŒããã³ã¹ãã³ãŽããšãª
ã³ãååæžæ¿æ¶²ãšããŠå®€ã®äžæ¹ã®ç²èåºç»å®€ã®èŠ
å®å¡©æº¶æ¶²ã«æ·»å ãããåæäºæž¬ã«åŸãã°ãã®ç³»ã«
æ·»å ããå šãªã³è質æ¿åºŠïŒ250ÎŒïœïŒã¯ãäºãå®
ããããé¢ç©ã®èã®ç²èè¡šé¢ã«åžçããããªã³è
質ã®å šéãšã»ãŒçããã€ããè©Šéšããããªã³è質
ã®åã ã¯Sigma Chemical瀟ïŒSt.Louisã
MissouriïŒããåŸããããã®ã§ãã€ãã åããªã³è質ã®æ·»å ã¯ïŒãïŒã®ç¯å²ã®ç²èã浞
ã溶液ã®PHã«äœçã®åœ±é¿ãåãŒããªãããšãå€æ
ãããPHèšã®é»æ°åºåã¯ïŒãã€ã³ãã«Bekcman
DynographïŒType R411ïŒã«æ¥ç¶ããã挿液äžã®
PHå€åã¯æéãšå ±ã«ç£èŠããããäžåºŠå®å®ãªåºæº
ç·ã«å°éãããšãå·å®³æ¿åºŠã®HClïŒ900ïœïŒïŒãç²
è宀ã«æ·»å ãããäžã€ã®å®éšã«ãããŠãå¯Ÿç §å®€ã®
挿è溶液ã®PHã¯H+ã宀ã®æŒ¿èåŽã«æµžéããåã«
å¹³å2.40åéå®å®ã§ãã€ãããªã³è質被èŠç²èã«
é¢ããŠãH+浞éã®å¹³åç Žå£ç¹ã¯6.70åã«å»¶é·ã
ãããæŽã«ç Žå£ç¹åŸã®H+æµã®é床ã¯ãªã³è質詊
æã®å Žåã«ã¯æªåŠçå¯Ÿç §äŸã®å Žåã®ããã«ã¯éã
ãªãã€ããããã¯ç 究ããåŸãããåŸæããæã
ãã§ããïŒç¬¬ïŒå³åç §ïŒã 第äºçªç®ã®äžé£ã®å®éšã«ãããŠã¯ãç²è質ã«æ·»
å ããåã ã®è¡šé¢æŽ»æ§å€ã®çžå¯Ÿæ¿åºŠããªã³è質ã®
å šéãäœãå€ããããšãªãå€åãããããããã®
å®éšã«ãããŠã¯ã135ÎŒïœã®DPLãåã 15ÎŒïœã®æ¬¡
ã®ãªã³è質ãå³ã¡ãPEãPGãPIããã³ã¹ãã€ã³
ãŽããšãªã³ãšå ±ã«æ·»å ãããæŽã«ãããã®å®éšã«
ãããŠãªã³è質æžæ¿æ¶²ãåºç»å®€ã«æ·»å ããããã®
çµæããªããŸãŒã ã®ç²åã圢æãããããããã®
ä¿®æ£ã«ããH+æµã挿èåŽã«èŠãããåã«æŽã«ç Ž
å£ç¹ã10.0åã«ãŸã§å»¶é·ããã äŸ ãªã³è質ä¿è·ã®in vivoç 究 åè¿°ã®å®éšã«ãããŠãæ¬çºæè çã¯èã®ç²èè¡š
é¢ã®in vitroã§ã®ãªã³è質ã®åŠçã¯ç²èè¡šç®ãé
éããŠç®¡è ããæ é€æµžæŒ¬æº¶æ¶²ãžã®H+ãæ¡æ£ãã
é床ãçžåœã«é 延ãããããšã瀺ãããåŸã€ãŠã
ãããã®çµæã¯ãªã³è質ãH+ã®ç®¡è ããçµç¹ãž
ã®é浞éãé ãããããšã«ããé žâèªçºèè é£ã«
察ããŠä¿è·ãè¡ãããšã瀺åãããæ¬çºæè çã¯
ãã®åé¡ãè©Šéšè©Šè¬ãé£éã«ããŠãŒã¬ã«ããçŽæ¥
èã®äžã«æäžããããšã®ã§ããæ¥æ§å¹œéçµçŽ®ã©ã
ãã«ãããŠæ€èšãããã©ããã¯äžæ©æé£ãããè©Š
éšæéã®éNembutal麻é äžã«ããããã©ããã¯
äºçŸ€ïŒïŒå¹ïŒçŸ€ïŒã«åãããè¡šé¢æŽ»æ§å€åŠçããš
称ãããäžæ¹ã®çŸ€ã¯æ¬¡ã®ãªã³è質ïŒ135ÎŒïœDPLã
15ÎŒïœã®DPPEãDPPGãDPPIããã³ã¹ãã€ã³ãŽ
ããšãªã³ã®å¡©æ°Žäžã®ãªããŸãŒã æžæ¿æ¶²0.5mlãå
ãåãã第äºã®çŸ€ïŒå¯Ÿç §äŸïŒã¯0.5mlã®å¡©æ°Žãè
ã®äžã«æ³šå°ãããïŒååŸã«äž¡çŸ€å ±ã«ïŒmlã®æœ°ççº
çæäžéã®0.6NHClãäžããããã麻é ããã
ãããåç©ã¯éªéãããã«45åéæŸçœ®ããããã®
åŸãããã¯æ®ºãããèãåé€ãã倧åœã«æ²¿ã€ãŠå
ãéãæ€æ»ãããæªåŠçå¯Ÿç §ã©ããã®æœ°ççºçå€
芳ãšã¯å¯Ÿç §çã«è¡šé¢æŽ»æ§å€ã§äºååŠçããã©ãã
ã¯å šäœçã«æ®ãã©æãã¯å šãé žèªçºæå·ãæããª
ãããã«èŠãããã ããäžã€ã®äžé£ã®in vivoå®éšã«ãããŠãåã
ã®ãªã³è質å³ã¡ãžãã«ããã€ã«ã¬ã·ãã³ããžãã«
ããã«ãã¹ãã¢ããžã«ãšã¿ããŒã«ã¢ãã³ãããã³
ãã¹ãã¢ããžã«ã³ãªã³ã®æ朰ç掻æ§ã®è©Šéšãè¡ã€
ããå®éšã¯åè¿°ãšåæ§ã«ããŠè¡ã€ããæŽã«ã©ãã
ã殺ãçŽåã«èã®è©ŠæãæãåºããŠãã¢ã°ããã³
åæãè¡ã€ããè©Šæã«ååšãããã¢ã°ããã³ã®é
ã¯èè žåºè¡ã®çšåºŠã«æ£æ¯äŸããåŸã€ãŠã朰çå掻
æ§ã«æ£æ¯äŸãããè©Šæã®æ朰ç掻æ§ã¯ã135ÎŒïœ
DPLã15ÎŒïœã®DPPEãDPPGãDPPIããã³ã¹ã
ã€ã³ãŽããšãªã³æ··åç©ã®çµåãã§äºååŠçããå
ç©ããæ€åºããããã¢ã°ããã³ã«å¯Ÿãããã¢ã°ã
ãã³ã«ãŠã³ãæ°ã®ããŒã»ã³ããšããŠæž¬å®ãããæ
朰ç掻æ§ã¯æ€åºããããã¢ã°ããã³ã®éã«åæ¯äŸ
ãããè¡šã¯åã ã®è©Šéšããããªã³è質ã®çžå¯Ÿç
æ朰ç掻æ§ã衚瀺ãããã®ã§ããã è¡š ãªã³è質 æŽ»æ§ æ··åç©ïŒ135ÎŒïœDPLãå15ÎŒïœã®DPPEãDPPGã
DPPIããã³Sph.ïŒ 100ïŒ ãžãã«ããã€ã«ã¬ã·ãã³ 15ÎŒïœ 95ïŒ 135ÎŒïœ 90ïŒ ãžãã«ããã€ã«ãã¹ãã¢ããžã«ãšã¿ããŒã«ã¢ãã³ 15ÎŒïœ 75â80ïŒ 135ÎŒïœ 70ïŒ ãã¹ãã¢ããžã«ã³ãªã³ 15ÎŒïœ 80ïŒ 135ÎŒïœ 80ïŒ åèšã®æ¬çºæã®é瀺å 容ã¯ã説æããã³äŸç€ºã®
ç®çã®ããã«ç¹å¥ã®å®æœæ æ§ã«åãããããã®ã§
ãããããããªããã説æãããå®æœæ æ§ã®æ¹æ³
ã«ãããŠå€ãã®ä¿®æ£ããã³å€æŽãæ¬çºæã®æ¬è³ªã
ãé¢ããããšãªããªããããããšãåœæ¥è ã«æã
ãã§ããããäŸãã°ãããã®æ£è ã«æäžããããª
ã³è質ã®éã¯å¹Žä»€ãäœéããã³æœ°çã®ç æ ã®çšåºŠ
ã«å¿ããŠå€åãåŸããã®ã§ãããæ¬çºæã®æ瀺å
容ã«äžè²«ããé©åœäžã€æå¹ãªæäžéã決å®ããèœ
åã¯åœæ¥è ã«æããã§ããããæŽã«ãç¹å¥ãªäºæ
ã«å¯Ÿé¢ããæã«èš±å®¹å¯èœãªæäžçµè·¯ã«å皮修æ£ã
è¡ãããšãåœæ¥è ã«ã¯æããã§ããããäŸãã°ã
幌å ã«ãããå£æ»æ§å šè žçã®æ²»çã¯å¹Œå ã®äººå·¥åŠ
æ¹ã«åæãªã³è質衚é¢æŽ»æ§å€ãè£çµŠããããšã«ã
ã容æã«è¡ãããã
第ïŒå³ã¯ãèã®PHïŒé
žæ§ïŒã«ãããŠã«ããªã³æ§
ãšãªãäž¡æ§ãªã³è質ãåŠäœã«ããŠè² ã«åž¯é»ããè¡š
é¢èã«åžçãããŠåäžãªçæ°Žæ§èã圢æãããã
æš¡åŒçã«è¡šç€ºãããã®ã§ããããã®çæ°Žæ§èã¯ã
æ°Žæ§æº¶æ¶²ã«æº¶è§£ããæ°ŽçŽ ã€ãªã³ããã³ä»ã®å·å®³ç©
質ãžã®éå£ãšããŠäœçšããã第ïŒå³ã¯ãin vitro
ïŒè©Šéšç®¡ã®äžïŒã«ãããã€ãã®èã®ç²èãééã
ãç²èãã挿èãžã®H+æµã«å¯Ÿãããªã³è質æžæ¿
液ã®ååšââÂãæ«
ãšãªãäž¡æ§ãªã³è質ãåŠäœã«ããŠè² ã«åž¯é»ããè¡š
é¢èã«åžçãããŠåäžãªçæ°Žæ§èã圢æãããã
æš¡åŒçã«è¡šç€ºãããã®ã§ããããã®çæ°Žæ§èã¯ã
æ°Žæ§æº¶æ¶²ã«æº¶è§£ããæ°ŽçŽ ã€ãªã³ããã³ä»ã®å·å®³ç©
質ãžã®éå£ãšããŠäœçšããã第ïŒå³ã¯ãin vitro
ïŒè©Šéšç®¡ã®äžïŒã«ãããã€ãã®èã®ç²èãééã
ãç²èãã挿èãžã®H+æµã«å¯Ÿãããªã³è質æžæ¿
液ã®ååšââÂãæ«
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ èè žæœ°ç眹æ£æ§æ£è ã«ãããèè žæœ°çç ã®æ²»
ççšçµæç©ã§ãã€ãŠã掻æ§æåãšããŠæ¬è³ªçã«äž¡
æ§ãªã³è質衚é¢æŽ»æ§å€ãæ£è ãžã®å éšæäžã«é©ã
ã圢æ ã§å«ãããšãç¹åŸŽãšããäžèšçµæç©ã ïŒ è¡šé¢æŽ»æ§å€ãçµå£æäžã«é©ãã圢æ ã«ããã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ äž¡æ§ãªã³è質衚é¢æŽ»æ§å€ãã¬ã·ãã³é¡ãã±ã
ã¢ãªã³é¡ãã¹ãã€ã³ãŽããšãªã³é¡ããã¹ãã¢ããž
ã«ã»ãªã³é¡åã¯ãããã®çµåãããéžã°ãããç¹
èš±è«æ±ã®ç¯å²ç¬¬ïŒé åã¯ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ äž¡æ§ãªã³è質衚é¢æŽ»æ§å€ããã¹ãã¢ããžã«ãš
ã¿ããŒã«ã¢ãã³ããã¹ãã¢ããžã«ã¢ãã¡ãã«ãšã¿
ããŒã«ã¢ãã³ããã¹ãã¢ããžã«ãžã¡ãã«ãšã¿ããŒ
ã«ã¢ãã³ããã¹ãã¢ããžã«ã³ãªã³ããã¹ãã¢ããž
ã«ã»ãªã³é¡åã¯ãããã®æ··åç©ããéžã°ãããç¹
èš±è«æ±ã®ç¯å²ç¬¬ïŒé åã¯ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ ãã¹ãã¢ãžãã«ååç©ããžãã«ããã€ã«çœ®æ
ãããŠãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæ
ç©ã ïŒ è¡šé¢æŽ»æ§å€ããã¹ãã¢ããžã«ã³ãªã³ããã¹ã
ã¢ããžã«ãšã¿ããŒã«ã¢ãã³ããã¹ãã¢ããžã«ã»ãª
ã³ããã³ã¹ãã€ã³ãŽããšãªã³ã®æ··åç©ã§ãããç¹
èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ ã¢ããªã³æ§ãªã³è質衚é¢æŽ»æ§å€ãäž¡æ§ãªã³è
質衚é¢æŽ»æ§å€ãšçµåãããããç¹èš±è«æ±ã®ç¯å²ç¬¬
ïŒé ã第ïŒé ã第ïŒé åã¯ç¬¬ïŒé ã®ããããäžé
ã«èšèŒã®çµæç©ã ïŒ ãã¹ãã¢ããžã«ã°ãªã»ããŒã«ããã³ïŒåã¯ã
ã¹ãã¢ããžã«ã€ãã·ããŒã«ãäž¡æ§ãªã³è質衚é¢æŽ»
æ§å€ãšçµåãããããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã第
ïŒé ã第ïŒé åã¯ç¬¬ïŒé ã®ããããäžé ã«èšèŒã®
çµæç©ã ïŒ äž¡æ§ãªã³è質衚é¢æŽ»æ§å€ããã¹ãã¢ããžã«ã³
ãªã³ããã¹ãã¢ããžã«ãšã¿ããŒã«ã¢ãã³ããã¹ã
ã¢ããžã«ã»ãªã³ããã³ã¹ãã€ã³ãŽããšãªã³åã¯ã
ããã®æ··åç©ããéžã°ãããã€è©²çµæç©ãæŽã«è¬
åŠçã«èš±å®¹å¯èœãªçšéå€ãå«ãã§ãªããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒïŒ æŽã«ããã¹ãã¢ããžã«ã°ãªã»ããŒã«ãã
ã³ïŒåã¯ãã¹ãã¢ããžã«ã€ãã·ããŒã«ãå«ããç¹
èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36745182A | 1982-04-12 | 1982-04-12 | |
| US367451 | 1982-04-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5946221A JPS5946221A (ja) | 1984-03-15 |
| JPH0569811B2 true JPH0569811B2 (ja) | 1993-10-01 |
Family
ID=23447229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58064396A Granted JPS5946221A (ja) | 1982-04-12 | 1983-04-12 | èè žæœ°çç æ²»ççšå»è¬çµæç© |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0092121B1 (ja) |
| JP (1) | JPS5946221A (ja) |
| DE (1) | DE3374914D1 (ja) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE452466B (sv) * | 1983-03-24 | 1987-11-30 | Paul Gunnar Embring | Blandning av vattenlosliga 3-fosfatidylestrar och kolin, sett att framstella denna och ett rektalt administrerbart preparat for tomning av grovtarm |
| DE3346525A1 (de) * | 1983-12-22 | 1985-07-04 | A. Nattermann & Cie GmbH, 5000 Köln | Pharmazeutische zubereitung mit speziellen 1,2-diacyl-glycero-3-phosphocholinen zur behandlung von erkrankungen im magen-darmbereich |
| US6759057B1 (en) | 1986-06-12 | 2004-07-06 | The Liposome Company, Inc. | Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs |
| ES2036593T3 (es) * | 1986-06-12 | 1993-06-01 | The Liposome Company, Inc. | Composiciones que utilizan medicamentos antiinflamatorios no esteroidales encapsulados en liposomas. |
| US5043329A (en) * | 1987-02-17 | 1991-08-27 | Board Of Regents, University Of Texas System | Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract |
| US4950656A (en) * | 1987-02-17 | 1990-08-21 | Board Of Regents, The University Of Texas System | Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract |
| US5032585A (en) * | 1987-02-17 | 1991-07-16 | Board Of Regents, The University Of Texas System | Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy |
| US4918063A (en) * | 1987-02-17 | 1990-04-17 | Board Of Regents, The University Of Texas System | Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract |
| US5260284A (en) * | 1987-02-17 | 1993-11-09 | Board Of Regents, The University Of Texas System | Methods employing unique mixtures of polar and neutral lipids and sterol for lung surfactant replacement therapy |
| ATE124262T1 (de) * | 1990-12-21 | 1995-07-15 | Microcarb Inc | Verwendung von wirtszellphospholipiden zur hemmung bakterieller besiedlung. |
| IT1263755B (it) * | 1991-09-16 | 1996-08-29 | Fidia Spa | Uso di esteri della colina con polisaccaridi acidi come agenti antiulcera e gastroprotettivi |
| US5478819A (en) * | 1993-06-23 | 1995-12-26 | Simo Tarpila | Phospholipid composition and use thereof |
| CA2217191C (en) * | 1995-04-03 | 2011-01-04 | Poul Bachmann | Pharmaceutical composition containing pectin and a phospholipid, used as an antidiarrheal and antiulcer agent |
| US5698537A (en) * | 1996-06-18 | 1997-12-16 | Clarion Pharmaceuticals Inc. | Method of lowering the viscosity of mucus |
| HUP0300236A3 (en) | 1997-02-21 | 2003-09-29 | Univ Tennessee Res Corp Knoxvi | Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis and process for their preparation |
| US6080787A (en) * | 1997-02-21 | 2000-06-27 | Abbott Laboratories | Methods for reducing the incidence of necrotizing enterocolitis |
| ES2211184T3 (es) * | 1998-08-06 | 2004-07-01 | Wolfgang Stremmel | Fosfatidilcolina como medicamento con efecto protector de mucosas. |
| AU1029500A (en) * | 1998-08-29 | 2000-03-21 | Miklos Ghyczy | Pharmaceutical and/or diet product |
| CN101505763A (zh) * | 2006-06-09 | 2009-08-12 | 鹿ç¹äž¹äŒææ¯å§æ¯å€§åŠå»çäžå¿ | éè¿èé磷èè°èå ç«ç³»ç» |
| EP2172203A1 (en) * | 2008-09-17 | 2010-04-07 | Giuliani S.P.A. | Pharmaceutical composition for the treatment of gastrointestinal irritation disorders |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5589225A (en) * | 1978-12-27 | 1980-07-05 | Nattermann A & Cie | Inflammation preventing medicine composition |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5060M (ja) * | 1965-12-22 | 1967-05-08 |
-
1983
- 1983-04-08 EP EP83103437A patent/EP0092121B1/en not_active Expired
- 1983-04-08 DE DE8383103437T patent/DE3374914D1/de not_active Expired
- 1983-04-12 JP JP58064396A patent/JPS5946221A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5589225A (en) * | 1978-12-27 | 1980-07-05 | Nattermann A & Cie | Inflammation preventing medicine composition |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0092121A1 (en) | 1983-10-26 |
| DE3374914D1 (en) | 1988-01-28 |
| EP0092121B1 (en) | 1987-12-16 |
| JPS5946221A (ja) | 1984-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0092121B1 (en) | Methods and compositions for treating gastro-intestinal ulcer diesease | |
| CA2003692C (en) | Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract and additional applications for surfactant replacement therapy and other conditions requiring rapid phospholipid _absorption to surfaces | |
| CA1310909C (en) | Methods and compositions for protecting the gastrointestinal tract | |
| Fabia et al. | Effects of Phosphatidylcholine and Phosphatidylinositol on Acetic-Acid-lnduced Colitis in the Rat | |
| US8252836B2 (en) | Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease | |
| US5043329A (en) | Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract | |
| Dial et al. | A role for milk phospholipids in protection against gastric acid: studies in adult and suckling rats | |
| US4950656A (en) | Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract | |
| US5134129A (en) | Methods employing unique mixtures of polar and neutral lipids for surfactant replacement therapy | |
| Hills | Gastric surfactant and the hydrophobic mucosal barrier. | |
| Maheshwari et al. | Preparation and pharmacological evaluation of silibinin liposomes | |
| US5260287A (en) | Polyphosphorylated organic compounds: compositions useful in protecting biological tissues | |
| JP7379348B2 (ja) | ç·ç¶çã®æ²»çã®ããã®çµæç©ããã³æ¹æ³ | |
| Lichtenberger et al. | Effect of ammonium ion on the hydrophobic and barrier properties of the gastric mucus gel layer: Implications on the role of ammonium in H. pyloriâinduced gastritis | |
| EP1973398B1 (en) | Use of inositol-tripyrophosphate in treating tumors mediated by angiogenesis | |
| US5260284A (en) | Methods employing unique mixtures of polar and neutral lipids and sterol for lung surfactant replacement therapy | |
| RU2133122C1 (ru) | ÐПЌпПзОÑОÑ, ПблаЎаÑÑÐ°Ñ ÑвПйÑÑваЌО ÑепаÑОÑПваÑÑ Ð±ÐžÐŸÐ»ÐŸÐ³ÐžÑеÑкОе ЌеЌбÑÐ°ÐœÑ | |
| DE60305592T2 (de) | Liposomenhaltiges Mittel zur Behandlung GefÀsserkrankungen | |
| KR860001802B1 (ko) | ìì í ë³µë°ìžµ ìí¬(è€èå±€ çè) | |
| Bengmark | Peritoneal conditioning: the role of the supply of natural membrane lipids | |
| JPH03106821A (ja) | æè «çå€ | |
| Deshmukh | Oral proliposomal delivery of cromolyn and tiludronate: Formulation and in vitro characterization in Caco-2 cells and isolated rat gut |